AR119184A1 - Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas - Google Patents

Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas

Info

Publication number
AR119184A1
AR119184A1 ARP200101717A ARP200101717A AR119184A1 AR 119184 A1 AR119184 A1 AR 119184A1 AR P200101717 A ARP200101717 A AR P200101717A AR P200101717 A ARP200101717 A AR P200101717A AR 119184 A1 AR119184 A1 AR 119184A1
Authority
AR
Argentina
Prior art keywords
salt
diffraction peaks
fumarate
crystalline form
characteristic diffraction
Prior art date
Application number
ARP200101717A
Other languages
English (en)
Spanish (es)
Inventor
Lei Yin
Zhenglin Yao
Original Assignee
Gan & Lee Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74040655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR119184(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gan & Lee Pharmaceuticals filed Critical Gan & Lee Pharmaceuticals
Publication of AR119184A1 publication Critical patent/AR119184A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP200101717A 2019-06-21 2020-06-18 Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas AR119184A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910542355 2019-06-21

Publications (1)

Publication Number Publication Date
AR119184A1 true AR119184A1 (es) 2021-12-01

Family

ID=74040655

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101717A AR119184A1 (es) 2019-06-21 2020-06-18 Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas

Country Status (16)

Country Link
US (1) US20220168302A1 (cg-RX-API-DMAC7.html)
EP (1) EP3988546A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022538076A (cg-RX-API-DMAC7.html)
KR (1) KR20220041090A (cg-RX-API-DMAC7.html)
CN (1) CN115708409B (cg-RX-API-DMAC7.html)
AR (1) AR119184A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020296048A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025944A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144546A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003438A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000502A2 (cg-RX-API-DMAC7.html)
IL (1) IL289231A (cg-RX-API-DMAC7.html)
MX (1) MX2022000051A (cg-RX-API-DMAC7.html)
PH (1) PH12021553151A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020253875A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202200964B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116113628B (zh) * 2020-08-31 2026-07-17 甘李药业山东有限公司 一种含cdk4/6抑制剂的药物组合物
WO2022242563A1 (zh) * 2021-05-17 2022-11-24 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
WO2024208265A1 (zh) * 2023-04-04 2024-10-10 苏州开拓药业股份有限公司 具有刺猬通路拮抗剂活性手性杂环化合物的盐型及其晶型

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途

Also Published As

Publication number Publication date
WO2020253875A1 (zh) 2020-12-24
EP3988546A4 (en) 2023-05-17
EP3988546A1 (en) 2022-04-27
KR20220041090A (ko) 2022-03-31
JP2022538076A (ja) 2022-08-31
US20220168302A1 (en) 2022-06-02
CN115708409B (zh) 2026-08-07
BR112021025944A2 (pt) 2022-02-08
PH12021553151A1 (en) 2022-07-25
IL289231A (en) 2022-02-01
CN115708409A (zh) 2023-02-21
CA3144546A1 (en) 2020-12-24
CL2021003438A1 (es) 2022-09-30
MX2022000051A (es) 2022-05-24
CO2022000502A2 (es) 2022-01-28
ZA202200964B (en) 2022-08-31
AU2020296048A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
MX2020002825A (es) Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia.
AR087672A1 (es) Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
BR112014013974A2 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
BR112022010377A2 (pt) Novos tiromiméticos
UY31069A1 (es) Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones
ECSP045221A (es) Sales de valsartan
MY137944A (en) Specific glucocorticoid compounds having anti-inflammatory activity
HUP0402454A2 (hu) Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
GT200000216A (es) Oxazolidinonas sustituidas y su uso.
SV1999000047A (es) Nuevas dihidropirimidinas fef. lea 32792-sv
EP1845081A4 (en) amide
BRPI0414447A (pt) derivado de quinazolina, composição farmacêutica, e, processo para a preparação de um derivado de quinazolina
ES2322602T3 (es) Compuestos heterotetraciclicos condensados y su uso como inhibidor de polimerasa del vhc.
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
IS2696B (is) Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð
NO20076695L (no) Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser
BRPI0409105A (pt) análogos de quinobenzoxazina substituìdos
EA200400208A1 (ru) Фенилацетамидотиазольные производные, способ их получения и их использования в качестве противоопухолевых средств
MX2016004963A (es) Sal y formas cristalinas de inhibidores de quinasa tipo polo-4.
BRPI0406704A (pt) Antagonistas de 5ht~7~ e agonistas inversos
UY29134A1 (es) Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones
EA200800439A1 (ru) Выбранные cgrp-антагонисты, способ их получения, а также их применение в качестве лекарственных средств
AR056082A1 (es) Formas cristalinas de clorhidrato de irinotecano (monoclorhidrato de 7-etil-10-[4-(1-piperidin)-1-piperidin]carboniloxicamptotecina trihidratado) y metodos de preparacion de las mismas
MX2023010606A (es) Formas de sales y sólidas de un inhibidor de cinasas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal